Keywords: national institutes of health nationalinstitutesofhealth national institute of arthritis and musculoskeletal and skin diseases (niams) nationalinstituteofarthritisandmusculoskeletalandskindiseasesniams dira deficiency of the interleukin-1 receptor antagonist deficiencyoftheinterleukin1receptorantagonist auto inflammatory disorder autoinflammatorydisorder nih niams nih image gallery nihimagegallery clinical research clinicalresearch NIAMS researchers Raphaela T. Goldbach-Mansky, M.D., M.H.S. (left) and Nicole Plass, R.N., M.P.A., U.S. Public Health Service, with a DIRA patient. NIAMS’ research has led to the identification and successful treatment of DIRA (deficiency of the interleukin-1 receptor antagonist), a genetic autoinflammatory disorder in children. Credit: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health NIAMS researchers Raphaela T. Goldbach-Mansky, M.D., M.H.S. (left) and Nicole Plass, R.N., M.P.A., U.S. Public Health Service, with a DIRA patient. NIAMS’ research has led to the identification and successful treatment of DIRA (deficiency of the interleukin-1 receptor antagonist), a genetic autoinflammatory disorder in children. Credit: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health |